Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic

Nature Medicine volume 25, pages547–553(2019)Cite this article

Subjects

Abstract

Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART interruption almost invariably leads to rebound viremia in infected individuals due to a long-lived latent reservoir of integrated proviruses. Therefore, ART must be administered on a life-long basis. Here we review recent preclinical and clinical studies suggesting that immunotherapy may be an alternative or an adjuvant to ART because, in addition to preventing new infections, anti-HIV-1 antibodies clear the virus, directly kill infected cells and produce immune complexes that can enhance host immunity to the virus.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

Fig. 1: Approved monoclonal antibodies and bNAbs tested in clinical trials.
Fig. 2: bNAb characteristics and virus and host factors determine efficacy of passive immunotherapy for HIV-1 prevention and therapy.

References

  1. 1.

    Bournazos, S., Wang, T. T., Dahan, R., Maamary, J. & Ravetch, J. V. Signaling by antibodies: recent progress. Annu. Rev. Immunol. 35, 285–311 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Kaplon, H. & Reichert, J. M. Antibodies to watch in 2019. MAbs 11, 219–238 (2019).

    CAS  PubMed  Google Scholar 

  3. 3.

    Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312 (2003).

    CAS  PubMed  Google Scholar 

  4. 4.

    Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144–4149 (2003).

    CAS  PubMed  Google Scholar 

  5. 5.

    Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10, 359–369 (1994).

    CAS  PubMed  Google Scholar 

  6. 6.

    Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024–1027 (1994).

    CAS  PubMed  Google Scholar 

  7. 7.

    Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100–1108 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Zwick, M. B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892–10905 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Gorny, M. K. et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66, 7538–7542 (1992).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615–622 (2005).

    CAS  PubMed  Google Scholar 

  11. 11.

    Mehandru, S. et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81, 11016–11031 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Scheid, J. F. et al. A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods 343, 65–67 (2009).

    CAS  PubMed  Google Scholar 

  13. 13.

    Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199–1204 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    West, A. P. Jr. et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156, 633–648 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Walker, L. M. & Burton, D. R. Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray. Nat. Rev. Immunol. 18, 297–308 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Mascola, J. R. & Haynes, B. F. HIV-1 neutralizing antibodies: understanding nature’s pathways. Immunol. Rev. 254, 225–244 (2013).

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Gama, L. & Koup, R. A. New-generation high-potency and designer antibodies: role in HIV-1 treatment. Annu. Rev. Med. 69, 409–419 (2018).

    CAS  PubMed  Google Scholar 

  18. 18.

    Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633–1637 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669–12682 (2014).

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Huang, J. et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45, 1108–1121 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268–E3277 (2012).

    CAS  PubMed  Google Scholar 

  23. 23.

    Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406–412 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Kwon, Y. D. et al. Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design. J. Virol. 90, 5899–5914 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl Acad. Sci. USA 111, 17624–17629 (2014).

    CAS  PubMed  Google Scholar 

  27. 27.

    Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55–62 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Emini, E. A. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728–730 (1992).

    CAS  PubMed  Google Scholar 

  29. 29.

    Mascola, J. R. et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009–4018 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207–210 (2000).

    CAS  PubMed  Google Scholar 

  31. 31.

    Shibata, R. et al. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J. Virol. 65, 3514–3520 (1991).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Li, J., Lord, C. I., Haseltine, W., Letvin, N. L. & Sodroski, J. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquir. Immune Defic. Syndr. 5, 639–646 (1992).

    CAS  PubMed  Google Scholar 

  33. 33.

    Pal, R. et al. Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J. Acquir. Immune Defic. Syndr. 33, 300–307 (2003).

    CAS  PubMed  Google Scholar 

  34. 34.

    Gautam, R. et al. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J. Virol. 86, 8516–8526 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Parren, P. W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340–8347 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Nishimura, Y. et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76, 2123–2130 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061–2074 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Huang, Y. et al. Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Hum. Vaccin. Immunother. 14, 2116–2127 (2018).

    PubMed  PubMed Central  Google Scholar 

  39. 39.

    Patel, P. et al. Estimating per-act HIV transmission risk: a systematic review. AIDS 28, 1509–1519 (2014).

    PubMed  PubMed Central  Google Scholar 

  40. 40.

    Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951–954 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105–109 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Moldt, B. et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86, 6189–6196 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642–645 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Gautam, R. et al. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat. Med. 24, 610–616 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Hinton, P. R. et al. An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176, 346–356 (2006).

    CAS  PubMed  Google Scholar 

  46. 46.

    Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10, 431–438 (1999).

    CAS  PubMed  Google Scholar 

  47. 47.

    Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118–122 (2012).

    CAS  PubMed  Google Scholar 

  48. 48.

    Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538–16543 (2013).

    CAS  PubMed  Google Scholar 

  49. 49.

    Diskin, R. et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210, 1235–1249 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Klein, F. et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J. Exp. Med. 211, 2361–2372 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Freund, N. T. et al. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci. Transl. Med. 9, eaal2144 (2017).

    PubMed  PubMed Central  Google Scholar 

  52. 52.

    Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277–280 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224–228 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989–999 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  55. 55.

    Jaworski, J. P. et al. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J. Virol. 87, 10447–10459 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559–563 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360–364 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Vittecoq, D. et al. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J. Infect. Dis. 165, 364–368 (1992).

    CAS  PubMed  Google Scholar 

  59. 59.

    Cavacini, L. A. et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 14, 545–550 (1998).

    CAS  PubMed  Google Scholar 

  60. 60.

    Armbruster, C. et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 16, 227–233 (2002).

    CAS  PubMed  Google Scholar 

  61. 61.

    Armbruster, C. et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J. Antimicrob. Chemother. 54, 915–920 (2004).

    CAS  PubMed  Google Scholar 

  62. 62.

    Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487–491 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).

    PubMed  Google Scholar 

  64. 64.

    Ledgerwood, J. E. et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289–301 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185–191 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Lu, C. L. et al. Enhanced clearance of HIV-1-infected cells by anti-HIV-1 broadly neutralizing antibodies in vivo. Science 352, 1001–1004 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997–1001 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  68. 68.

    Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556–560 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Cohen, Y. Z. et al. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J. Exp. Med. 215, 2311–2324 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037–2050 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Cohen, Y. Z. et al. Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against Clade B clinical isolates produced in peripheral blood mononuclear cells. J. Virol. 92, e01883–17 (2018).

    PubMed  PubMed Central  Google Scholar 

  72. 72.

    Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701–1707 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479–484 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  74. 74.

    Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921–18925 (2012).

    CAS  PubMed  Google Scholar 

  75. 75.

    Julg, B. et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci. Transl. Med. 9, eaal1321 (2017).

    PubMed  PubMed Central  Google Scholar 

  76. 76.

    Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).

    PubMed  PubMed Central  Google Scholar 

  77. 77.

    Gilbert, P. B. et al. Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials. Stat. Commun. Infect. Dis. 9, 20160001 (2017).

    PubMed  PubMed Central  Google Scholar 

  78. 78.

    Wagh, K. et al. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog. 14, e1006860 (2018).

    PubMed  PubMed Central  Google Scholar 

  79. 79.

    Doria-Rose, N. A. et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J. Virol. 86, 3393–3397 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  80. 80.

    Kong, R. et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J. Virol. 89, 2659–2671 (2015).

    PubMed  Google Scholar 

  81. 81.

    Sengupta, S. & Siliciano, R. F. Targeting the latent reservoir for HIV-1. Immunity 48, 872–895 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  82. 82.

    Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183–188 (1997).

    CAS  PubMed  Google Scholar 

  83. 83.

    Lorenzi, J. C. et al. Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proc. Natl Acad. Sci. USA 113, E7908–E7916 (2016).

    CAS  PubMed  Google Scholar 

  84. 84.

    Hosmane, N. N. et al. Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics. J. Exp. Med. 214, 959–972 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  85. 85.

    Wang, Z. et al. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proc. Natl Acad. Sci. USA 115, E2575–E2584 (2018).

    CAS  PubMed  Google Scholar 

  86. 86.

    Walker, B. D. & Yu, X. G. Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 13, 487–498 (2013).

    CAS  PubMed  Google Scholar 

  87. 87.

    Kalialis, L. V., Drzewiecki, K. T. & Klyver, H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 19, 275–282 (2009).

    PubMed  Google Scholar 

  88. 88.

    Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655 (1994).

    CAS  PubMed  PubMed Central  Google Scholar 

  89. 89.

    Walker, B. D. et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328, 345–348 (1987).

    CAS  PubMed  Google Scholar 

  90. 90.

    Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381–385 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  91. 91.

    Dhodapkar, K. M. et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl Acad. Sci. USA 102, 2910–2915 (2005).

    CAS  PubMed  Google Scholar 

  92. 92.

    Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).

    CAS  PubMed  Google Scholar 

  93. 93.

    Margolis, D. M. & Archin , N. M. Proviral latency, persistent human immunodeficiency virus infection, and the development of latency reversing agents. J. Infect. Dis. 215, S111–S118 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  94. 94.

    Cohn, L. B. et al. Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. Nat. Med. 24, 604–609 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  95. 95.

    Shan, L.et al. Transcriptional reprogramming during effector-to-memory transition renders CD4+ T cells permissive for latent HIV-1 infection. Immunity 47, 766–775 e763 2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  96. 96.

    Cockerham, L. R., Hatano, H. & Deeks, S. G. Post-treatment controllers: role in HIV “cure” research. Curr. HIV/AIDS Rep. 13, 1–9 (2016).

    PubMed  Google Scholar 

  97. 97.

    Namazi, G. et al. The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies. J. Infect. Dis. 218, 1954–1963 (2018).

    PubMed  Google Scholar 

  98. 98.

    Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).

    PubMed  PubMed Central  Google Scholar 

  99. 99.

    Scott-Algaram, D. et al. Post-treatment controllers have particular NK cells with high anti-HIV capacity: VISCONTI study. Conference on Retroviruses and Opportunistic Infections, abstr. 52 (2015).

Download references

Acknowledgements

We thank members of the Klein and Nussenzweig laboratories for discussion. This work was supported by the NIH/National Institute of Allergy and Infectious Diseases Grant (U01AI129825), the Einstein-Rockefeller-CUNY Center for AIDS Research (1P30AI124414-01A1) and the BEAT-HIV Delaney grant UM1 AI126620 (M.C.); the Heisenberg-Program of the DFG (KL 2389/2-1), the European Research Council (ERC-StG639961) and the German Center for Infection Research (DZIF) (F.K.); the Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) grants OPP1092074 and OPP1124068 and the NIH grants 1UM1 AI100663 and R01AI-129795 (M.C.N.); and the Robertson fund.

Author information

Affiliations

  1. Laboratory of Molecular Immunology, Rockefeller University, New York, NY, USA

    Marina Caskey & Michel C. Nussenzweig

  2. Laboratory of Experimental Immunology, Institute of Virology, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany

    Florian Klein

  3. Center for Molecular Medicine Cologne (CMMC), University of Cologne, Faculty of Medicine, Cologne, Germany

    Florian Klein

  4. German Center for Infection Research, partner site Bonn–Cologne, Cologne, Germany

    Florian Klein

  5. Howard Hughes Medical Institute, Rockefeller University, New York, NY, USA

    Michel C. Nussenzweig

Authors
  1. Marina Caskey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florian Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michel C. Nussenzweig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Marina Caskey or Florian Klein or Michel C. Nussenzweig.

Ethics declarations

Competing interests

There are patents on 3BNC117 and 10-1074, on which M.C.N is an inventor.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Caskey, M., Klein, F. & Nussenzweig, M.C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med 25, 547–553 (2019). https://doi.org/10.1038/s41591-019-0412-8

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing